Neuro endocrinology letters · 2025
Hypolipidemic, anti-inflammatory, and neurotrophic effects of a multicomponent nutraceutical containing berberine, bergamot, and amaranth in mild-to-moderate hypercholesterolemia.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Minoretti Piercarlo, Lista Simone, Khoramipour Kayvan, Crespo-Escobar Paula, Santos-Lozano Alejandro, Emanuele Enzo
Аннотация
BACKGROUND: Nutraceutical combinations represent a potential strategy for managing mild hypercholesterolemia in patients who cannot tolerate or do not require statin therapy. In this two-group prospective comparative study, we evaluated the effects of a nutraceutical formulation containing berberine (500 mg), bergamot extract (200 mg), and Amaranthus cruentus extract (30 mg) on lipid, inflammatory, and neurotrophic parameters in low-risk subjects with mild-to-moderate hypercholesterolemia.
METHODS: Sixty subjects with low-density-lipoprotein cholesterol (LDL-C) 115-180 mg/dL, total cholesterol (TC) 200-260 mg/dL, triglycerides <250 mg/dL, and cardiovascular risk < 20% received either one tablet daily (Group 1, n = 30) or two tablets daily (Group 2, n = 30) of the study supplement for 8 weeks. Primary outcomes included TC, LDL-C, oxidized LDL (oxLDL), and high-density-lipoprotein cholesterol (HDL-C). Secondary outcomes were triglycerides, high-sensitivity C-reactive protein (hs-CRP), and serum brain-derived neurotrophic factor (BDNF).
RESULTS: Both regimens significantly reduced TC and LDL-C at 8 weeks. Group 2 demonstrated superior reductions in LDL-C (-25.2% versus -14.5%, p < 0.05), oxLDL (-23.1% versus -11.8%, p < 0.05), and hs-CRP (-31.3% versus -6.7%, p < 0.001) compared with Group 1. Group 2 also showed significant increases in HDL-C (+14.9% versus +2.2%, p < 0.05) and BDNF levels (+16.3% versus +2.7%, p<0.001). Both regimens were well-tolerated with no adverse events or hepatic/muscular parameter changes.
CONCLUSION: This nutraceutical formulation effectively and safely reduced TC and LDL-C in low-risk subjects with mild hypercholesterolemia. The twice-daily regimen provided superior lipid improvements and increased HDL-C and BDNF levels, indicating additional antioxidant, anti-inflammatory, and neuroprotective properties warranting further investigation.
METHODS: Sixty subjects with low-density-lipoprotein cholesterol (LDL-C) 115-180 mg/dL, total cholesterol (TC) 200-260 mg/dL, triglycerides <250 mg/dL, and cardiovascular risk < 20% received either one tablet daily (Group 1, n = 30) or two tablets daily (Group 2, n = 30) of the study supplement for 8 weeks. Primary outcomes included TC, LDL-C, oxidized LDL (oxLDL), and high-density-lipoprotein cholesterol (HDL-C). Secondary outcomes were triglycerides, high-sensitivity C-reactive protein (hs-CRP), and serum brain-derived neurotrophic factor (BDNF).
RESULTS: Both regimens significantly reduced TC and LDL-C at 8 weeks. Group 2 demonstrated superior reductions in LDL-C (-25.2% versus -14.5%, p < 0.05), oxLDL (-23.1% versus -11.8%, p < 0.05), and hs-CRP (-31.3% versus -6.7%, p < 0.001) compared with Group 1. Group 2 also showed significant increases in HDL-C (+14.9% versus +2.2%, p < 0.05) and BDNF levels (+16.3% versus +2.7%, p<0.001). Both regimens were well-tolerated with no adverse events or hepatic/muscular parameter changes.
CONCLUSION: This nutraceutical formulation effectively and safely reduced TC and LDL-C in low-risk subjects with mild hypercholesterolemia. The twice-daily regimen provided superior lipid improvements and increased HDL-C and BDNF levels, indicating additional antioxidant, anti-inflammatory, and neuroprotective properties warranting further investigation.